IRIS Accounts Production v24.3.2.46 14953331 Board of Directors 22.6.23 30.6.24 30.6.24 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh149533312023-06-21149533312024-06-30149533312023-06-222024-06-30149533312023-06-2114953331ns15:EnglandWales2023-06-222024-06-3014953331ns14:PoundSterling2023-06-222024-06-3014953331ns10:Director12023-06-222024-06-3014953331ns10:PrivateLimitedCompanyLtd2023-06-222024-06-3014953331ns10:SmallEntities2023-06-222024-06-3014953331ns10:AuditExempt-NoAccountantsReport2023-06-222024-06-3014953331ns10:SmallCompaniesRegimeForDirectorsReport2023-06-222024-06-3014953331ns10:SmallCompaniesRegimeForAccounts2023-06-222024-06-3014953331ns10:FullAccounts2023-06-222024-06-3014953331ns10:OrdinaryShareClass12023-06-222024-06-3014953331ns10:Director22023-06-222024-06-3014953331ns10:RegisteredOffice2023-06-222024-06-3014953331ns5:CurrentFinancialInstruments2024-06-3014953331ns5:Non-currentFinancialInstruments2024-06-3014953331ns5:ShareCapital2024-06-3014953331ns5:RetainedEarningsAccumulatedLosses2024-06-3014953331ns5:AdditionsToInvestments2024-06-3014953331ns5:CostValuation2024-06-3014953331ns5:WithinOneYearns5:CurrentFinancialInstruments2024-06-3014953331ns10:OrdinaryShareClass12024-06-30
REGISTERED NUMBER: 14953331 (England and Wales)









PHARMEX HOLDINGS LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE PERIOD

22 JUNE 2023 TO 30 JUNE 2024






PHARMEX HOLDINGS LIMITED (REGISTERED NUMBER: 14953331)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE PERIOD 22 JUNE 2023 TO 30 JUNE 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


PHARMEX HOLDINGS LIMITED

COMPANY INFORMATION
FOR THE PERIOD 22 JUNE 2023 TO 30 JUNE 2024







DIRECTORS: Mrs J K Sembhi
S Sembhi





REGISTERED OFFICE: 121 Henley Road
Ilford
IG1 2TS





REGISTERED NUMBER: 14953331 (England and Wales)






PHARMEX HOLDINGS LIMITED (REGISTERED NUMBER: 14953331)

BALANCE SHEET
30 JUNE 2024

Notes £    £   
FIXED ASSETS
Investments 4 2,056,480

CURRENT ASSETS
Debtors 5 3,074
Cash at bank and in hand 4,556
7,630
CREDITORS
Amounts falling due within one year 6 1,363,642
NET CURRENT LIABILITIES (1,356,012 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

700,468

CREDITORS
Amounts falling due after more than one
year

7

740,733
NET LIABILITIES (40,265 )

CAPITAL AND RESERVES
Called up share capital 9 4
Retained earnings (40,269 )
SHAREHOLDERS' FUNDS (40,265 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 30 June 2024.

The members have not required the company to obtain an audit of its financial statements for the period ended 30 June 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

PHARMEX HOLDINGS LIMITED (REGISTERED NUMBER: 14953331)

BALANCE SHEET - continued
30 JUNE 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 20 March 2025 and were signed on its behalf by:





Mrs J K Sembhi - Director


PHARMEX HOLDINGS LIMITED (REGISTERED NUMBER: 14953331)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD 22 JUNE 2023 TO 30 JUNE 2024

1. STATUTORY INFORMATION

Pharmex Holdings Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Group accounts
In preparing these financial statements advantage has been taken of the exemptions conferred by section 399 of the Companies Act 2006 not to prepare consolidated group accounts, on the grounds that the group is entitled to the benefit of those exemptions as a small size group. These financial statements therefore present information about the company as an individual undertaking and not about its group.

Going concern
The financial statements have been prepared on a going concern basis which assumes that the company will continue in operational existence for the foreseeable future. In making their assessment, the director has reviewed the balance sheet, the likely future cashflows of the business and has considered the facilities that are available to the company along with their continued support.

At the date of approving the financial statements the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future and that the going concern basis of accounting remains appropriate. The director continues to adopt the going concern basis of accounting in preparing the financial statements.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' section 33.1A, not to disclose related party transactions with wholly owned subsidiaries within the group.

Significant judgements and estimates
In the application of the company's accounting policies, which are described in note 2, management is required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on a ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

PHARMEX HOLDINGS LIMITED (REGISTERED NUMBER: 14953331)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 22 JUNE 2023 TO 30 JUNE 2024

2. ACCOUNTING POLICIES - continued

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Investments in subsidiary undertakings are recognised at costs and reviewed periodically for any indication of impairment.

Dividends or other distributions received from the associated company are recognised in the income statement during the period which it relates too.

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Provisions
Provisions are recognised when the company has an obligation at the balance sheet date as a result of a past event, it is probable that an outflow of economic benefit will be required in settlement and the amount cab be reliable estimated.

PHARMEX HOLDINGS LIMITED (REGISTERED NUMBER: 14953331)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 22 JUNE 2023 TO 30 JUNE 2024

2. ACCOUNTING POLICIES - continued

Cash and cash equivalents
Financial instruments
The company has elected to apply the provisions of Section 11 "Basic Financial Instruments".
Financial instruments are recognised when the company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realize the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include trade and other debtors, loans to related companies and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortized cost using the effective interest method unless the arrangement constitutes a financing transaction, where the financial asset is measured at the present value of the future receipts discounted at a market rate of interest.

Basic financial liabilities
Basic financial liabilities, including trade and other creditors, loans to related companies and bank loans are initially recognised at transaction price unless the arrangement constitutes a financial transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest.

Impairment
Assets not measured at fair value are reviewed for any indication that the asset may be impaired at each balance sheet date. If such indication exists, the recoverable amount of the asset, or the assets cash generating unit, is estimated and compared to the carrying amount. Where the carrying amount exceeds its recoverable amount, an impairment loss is recognised in profit and loss unless the asset is carried at a revalued amount where the impairment loss is a revaluation decrease.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 2 .

4. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
Additions 2,056,480
At 30 June 2024 2,056,480
NET BOOK VALUE
At 30 June 2024 2,056,480

PHARMEX HOLDINGS LIMITED (REGISTERED NUMBER: 14953331)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 22 JUNE 2023 TO 30 JUNE 2024

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
£   
Other debtors 3,074

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
£   
Bank loans and overdrafts 107,340
Amounts owed to group undertakings 969,969
Other creditors 286,333
1,363,642

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN
ONE YEAR
£   
Bank loans 740,733

8. SECURED DEBTS

The company's bankers hold a fixed and floating charge including a negative pledge over all company properties and related undertakings.

9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal
value: £   
4 Ordinary £1 4